Related Experiment Videos
Angiogenesis and breast cancer
1Breast Evaluation Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hematology/Oncology Clinics of North America
|February 1, 1994
Summary
Antiangiogenesis therapy shows promise for treating cancers like breast cancer. Individual patient response, influenced by genetics, is key to antiangiogenic drug efficacy and future treatment personalization.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Antiangiogenesis is a promising therapeutic strategy for various diseases, including breast cancer.
- Historically, antiangiogenesis has been theoretical, but recent advancements suggest potential clinical applications.
- Early clinical trials for antiangiogenic agents are being planned, focusing initially on safety and adjuvant settings.
Purpose of the Study:
- To explore the potential of antiangiogenesis as a therapeutic modality for human malignancies, particularly breast cancer.
- To investigate the role of individual response and genetic factors in the efficacy of antiangiogenic agents.
- To discuss the future implications of antiangiogenic therapy in personalized cancer treatment.
Main Methods:
- Review of recent studies on antiangiogenic agents and their potential clinical applications.
- Discussion of preliminary clinical trial designs focusing on safety and early-stage disease.
- Investigation of the antiangiogenic activity of maltose tetrapalmitate (MTP) in inbred mice models.
Main Results:
- Specific antiangiogenic agents show potential for effectiveness and safety.
- Genetic responsiveness in mice correlates directly with antiangiogenic and antitumor effects of MTP.
- Mice unable to respond to MTP did not show protection against tumor growth.
Conclusions:
- Antiangiogenic therapy is advancing from theory to potential clinical practice, especially in early-stage and adjuvant settings.
- Combination therapies involving antiangiogenic agents with chemotherapy or endocrine therapy are likely to be most effective.
- Future cancer treatment may involve assessing an individual's "angiogenic profile" for personalized therapy selection, similar to current biomarker-based approaches.